More with atrial fibrillation, anticoagulants since the coming of NOAK

More with atrial fibrillation, anticoagulants since the coming of NOAK

Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of pati...

Full description

Saved in:
Bibliographic Details
Published in:Läkartidningen Vol. 112
Main Authors: Forslund, Tomas, von Euler, Mia, Johnsson, Hans, Holmström, Margareta, Wettermark, Björn, Hjemdahl, Paul
Format: Journal Article
Language:English
Swedish
Published: Sweden 06-01-2015
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anticoagulants - therapeutic use
Antithrombins - therapeutic use
Aspirin - therapeutic use
Atrial Fibrillation - drug therapy
Atrial Fibrillation - prevention & control
Benzimidazoles - therapeutic use
beta-Alanine - analogs & derivatives
beta-Alanine - therapeutic use
Cohort Studies
Dabigatran
Drug Prescriptions - statistics & numerical data
Drug Utilization
Factor Xa Inhibitors - therapeutic use
Female
Humans
Male
Middle Aged
Morpholines - therapeutic use
Pyrazoles - therapeutic use
Pyridones - therapeutic use
Risk Assessment
Rivaroxaban
Thiophenes - therapeutic use
Warfarin - therapeutic use
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of patients treated with warfarin or NOAC has increased from 47 % to 58 % in 2013. The use of acetylsalicylic acid in patients is decreasing rapidly in patients with AF. NOAC are mostly prescribed by specialists and are mainly used in younger patients with lower CHA2DS2-VASc scores and lower risk for renal insufficiency and bleeding.
ISSN:1652-7518